• Je něco špatně v tomto záznamu ?

Interaction of Adenosine, Modified Using Carborane Clusters, with Ovarian Cancer Cells: A New Anticancer Approach against Chemoresistance

K. Bednarska-Szczepaniak, E. Przelazły, KD. Kania, M. Szwed, M. Litecká, B. Grűner, ZJ. Leśnikowski

. 2021 ; 13 (15) : . [pub] 20210730

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21024263

Grantová podpora
2015/17/B/NZ3/03764 Narodowe Centrum Nauki

Platinum compounds remain the first-line drugs for the treatment of most lethal gynecological malignancies and ovarian cancers. Acquired platinum resistance remains a major challenge in gynecological oncology. Considering the unique physicochemical properties of the metallacarboranes modifier and the significant role of nucleoside derivatives as anticancer antimetabolites, we designed and synthesized a set of adenosine conjugates with metallacarboranes containing iron, cobalt, or chromium as semi-abiotic compounds that influence the cisplatin sensitivity of ovarian cancer cells. Adherent cultures of ovarian carcinoma cell lines and multicellular spheroids, ranging from sensitive to highly resistant including experimental cell lines "not responding" to platinum drugs were used. Iron-containing metallacarborane conjugates showed the best anticancer activity, especially against resistant cells. Compound modified at the C2' nucleoside position showed the best activity in resistant cancer cells and highly resistant cancer spheroids exposed to cisplatin, increasing cell cycle arrest, apoptosis or necrosis, and reactive oxygen species production. Moreover, it showed high cellular accumulation and did not induce cross-resistance to cisplatin, carboplatin, doxorubicin, paclitaxel, or gemcitabine in long-term cultures. The reference nido-carborane derivative (no metal ions) and unmodified nucleosides were not as effective. These findings indicate that metallacarborane modification of adenosine may sensitize ovarian cancer cells to cisplatin in combination treatment.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21024263
003      
CZ-PrNML
005      
20211013134009.0
007      
ta
008      
211006s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/cancers13153855 $2 doi
035    __
$a (PubMed)34359756
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Bednarska-Szczepaniak, Katarzyna $u Laboratory of Medicinal Chemistry, Polish Academy of Sciences, Institute of Medical Biology, 106 Lodowa, 92-232 Lodz, Poland
245    10
$a Interaction of Adenosine, Modified Using Carborane Clusters, with Ovarian Cancer Cells: A New Anticancer Approach against Chemoresistance / $c K. Bednarska-Szczepaniak, E. Przelazły, KD. Kania, M. Szwed, M. Litecká, B. Grűner, ZJ. Leśnikowski
520    9_
$a Platinum compounds remain the first-line drugs for the treatment of most lethal gynecological malignancies and ovarian cancers. Acquired platinum resistance remains a major challenge in gynecological oncology. Considering the unique physicochemical properties of the metallacarboranes modifier and the significant role of nucleoside derivatives as anticancer antimetabolites, we designed and synthesized a set of adenosine conjugates with metallacarboranes containing iron, cobalt, or chromium as semi-abiotic compounds that influence the cisplatin sensitivity of ovarian cancer cells. Adherent cultures of ovarian carcinoma cell lines and multicellular spheroids, ranging from sensitive to highly resistant including experimental cell lines "not responding" to platinum drugs were used. Iron-containing metallacarborane conjugates showed the best anticancer activity, especially against resistant cells. Compound modified at the C2' nucleoside position showed the best activity in resistant cancer cells and highly resistant cancer spheroids exposed to cisplatin, increasing cell cycle arrest, apoptosis or necrosis, and reactive oxygen species production. Moreover, it showed high cellular accumulation and did not induce cross-resistance to cisplatin, carboplatin, doxorubicin, paclitaxel, or gemcitabine in long-term cultures. The reference nido-carborane derivative (no metal ions) and unmodified nucleosides were not as effective. These findings indicate that metallacarborane modification of adenosine may sensitize ovarian cancer cells to cisplatin in combination treatment.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Przelazły, Ewelina $u Laboratory of Medicinal Chemistry, Polish Academy of Sciences, Institute of Medical Biology, 106 Lodowa, 92-232 Lodz, Poland
700    1_
$a Kania, Katarzyna Dominika $u Laboratory of Transcriptional Regulation, Polish Academy of Sciences, Institute of Medical Biology, 106 Lodowa, 92-232 Lodz, Poland $u Laboratory of Virology, Polish Academy of Sciences, Institute of Medical Biology, 106 Lodowa, 92-232 Lodz, Poland
700    1_
$a Szwed, Marzena $u Department of Medical Biophysics, Institute of Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, 90-236 Lodz, Poland
700    1_
$a Litecká, Miroslava $u Institute of Inorganic Chemistry of the Czech Academy of Sciences, Hlavní 1001, 250 68 Rež, Czech Republic
700    1_
$a Grűner, Bohumír $u Institute of Inorganic Chemistry of the Czech Academy of Sciences, Hlavní 1001, 250 68 Rež, Czech Republic
700    1_
$a Leśnikowski, Zbigniew J $u Laboratory of Medicinal Chemistry, Polish Academy of Sciences, Institute of Medical Biology, 106 Lodowa, 92-232 Lodz, Poland
773    0_
$w MED00173178 $t Cancers $x 2072-6694 $g Roč. 13, č. 15 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34359756 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20211006 $b ABA008
991    __
$a 20211013134006 $b ABA008
999    __
$a ind $b bmc $g 1708254 $s 1144760
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 13 $c 15 $e 20210730 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
GRA    __
$a 2015/17/B/NZ3/03764 $p Narodowe Centrum Nauki
LZP    __
$a Pubmed-20211006

Najít záznam

Citační ukazatele

Možnosti archivace